Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Gross Margin for 2 consecutive years, with 80.11% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 2065.0% year-over-year to 80.11%, compared with a TTM value of 83.27% through Sep 2025, up 2735.0%, and an annual FY2024 reading of 69.35%, changed N/A over the prior year.
  • Gross Margin was 80.11% for Q3 2025 at X4 Pharmaceuticals, down from 83.48% in the prior quarter.
  • Across five years, Gross Margin topped out at 83.63% in Q1 2025 and bottomed at 52.4% in Q2 2024.